

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM356507

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMORGAN CHASE BANK, N.A.	FORMERLY THE CHASE MANHATTAN BANK	09/21/2015	CORPORATION:
RECEIVING PARTY DATA			
Name:	PHARMACY CORPORATION OF AMERICA		
Street Address:	1901 CAMPUS PLACE		
City:	LOUISVILLE		
State/Country:	KENTUCKY		
Postal Code:	40299		
Entity Type:	CORPORATION: CALIFORNIA		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	1554991		
Registration Number:	1528564	PHARMACY CORPORATION OF AMERICA	
Registration Number:	2304597	PHARMERICA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	aharrison@stites.com		
Correspondent Name:	STITES & HARBISON, PLLC		
Address Line 1:	400 WEST MARKET ST.		
Address Line 2:	SUITE 1800		
Address Line 4:	LOUISVILLE, KENTUCKY 40202		
ATTORNEY DOCKET NUMBER:	PH062/000PH		
NAME OF SUBMITTER:	Aimee Harrison		
SIGNATURE:	/aimee harrison/		
DATE SIGNED:	09/28/2015		
Total Attachments: 4			
source=Release_Security_Interest#page1.tif			
source=Release_Security_Interest#page2.tif			

OP \$90.00 1554991

source=Release_Security_Interest#page3.tif

source=Release_Security_Interest#page4.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release"), made as of the date below, is granted by JPMORGAN CHASE BANK, N.A., formerly THE CHASE MANHATTAN BANK, in its capacity as collateral agent pursuant to the Collateral Agreement (as defined below) (in such capacity, the "Collateral Agent") in favor of the Borrower (as defined below) and the Subsidiary Loan Parties (as defined below) and their respective successors and assigns party to the Security Agreements referred to below (collectively, the "Pledgors").

WHEREAS, Pharmacy Corporation of America and/or its affiliates (the "Borrower") and JPMORGAN CHASE BANK, N.A., formerly THE CHASE MANHATTAN BANK, as administrative agent (in such capacity, the "Administrative Agent") and Collateral Agent, have entered into certain Credit Agreements, dated April 20, 2000, and August 29, 2001 (collectively the "Credit Agreements");

WHEREAS, the Borrower and the affiliates of the Borrower from time to time party thereto (collectively, the "Subsidiary Loan Parties") and the Collateral Agent have entered into that certain Guarantee and Collateral Agreements dated as of April 20, 2000, and August 29, 2001 (the "Collateral Agreements");

WHEREAS, the Collateral Agent and the Pledgors thereto have entered into certain Patent and Trademark Security Agreements, dated April 20, 2000, and August 29, 2001, and certain Trademark Security Agreements, dated as of April 20, 2000, and August 29, 2001 (collectively, the "Security Agreements"; all capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Security Agreements);

WHEREAS, pursuant to the terms and conditions of the Credit Agreement, Collateral Agreement and Security Agreements, the Pledgors granted to the Collateral Agent a security interest under the Patent and Trademark Collateral and the Trademark Collateral (collectively, the "Released IP") including, without limitation, the Trademark registrations and applications set forth on Schedule I hereto;

WHEREAS, the Security Agreements relating to the Released IP have been recorded with the Assignments Division of the U.S. Patent and Trademark Office on (a) June 26, 2000, at Reel 2103 and Frame 0001, and on (b) September 27, 2001, at Reel 2376 and Frame 0011;

WHEREAS, the Pledgors have paid all of their outstanding indebtedness under the Credit Agreement which is secured by the Security Agreements and have requested that the Collateral Agent release its security interest in the Released IP;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby confirms that it has terminated the Security Agreements, and has terminated, cancelled, re-pledged, reassigned and released any and all security interests it has against the Released IP, without warranty or recourse.

If and to the extent the Collateral Agent has acquired any right, title or interest to any of the Released IP, it hereby assigns and transfers such rights, title or interest to the respective Pledgors. The Collateral Agent shall take all further actions, and provide to the Pledgors and their successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Pledgors to more fully and effectively effectuate the purposes of this Release. The execution and delivery of this Release and any further documents and the performance of any actions


by the Collateral Agent are made without representation or warranty by, or recourse to, the Collateral Agent.

This Release shall be construed in accordance with and governed by the law of the State of New York.


(Signature page follows)

IN WITNESS WHEREOF, the Collateral Agent has caused this Release of Security Interest in the Released IP to be executed and delivered by its duly authorized officer as of the date first set forth above.

JP MORGAN CHASE BANK, N.A.,
as Collateral Agent,

By: 
Name: Dawn L. LeeLum
Title: Executive Director

SCHEDULE I

Record Owner	Mark	Registration Date	Registration No.
PharMerica Corporation		September 5, 1989	1554991
PharMerica Corporation	PHARMACY CORPORATION OF AMERICA	March 7, 1989	1528564
PharMerica Corporation	PHARMERICA	December 28, 1999	2304597